Pharmaceuticals, Biotechnology and Life Sciences
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a…
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,…
LONDON, April 29, 2025 (GLOBE NEWSWIRE) — Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with…
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agentMELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE)…
– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R&D…
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the…
Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to…
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the…
– Oral presentation to include preclinical data supporting the clinical advancement of ABO-101 for the treatment of primary hyperoxaluria type 1…
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced…